Published in Cancer Res on June 01, 1997
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Pulmonary preinvasive neoplasia. J Clin Pathol (2001) 2.02
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci U S A (1998) 1.86
Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res (2010) 1.51
Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis (2007) 1.48
Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax (2003) 1.28
Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A (1997) 1.24
Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol (2000) 1.02
Preneoplastic lesions of the lung. Respir Res (2002) 1.01
Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia. Br J Cancer (1999) 0.96
Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol (2000) 0.91
Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer (2000) 0.89
Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res (2010) 0.89
A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer (1999) 0.88
High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis. Neoplasia (2012) 0.87
Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol (2003) 0.87
Control of 5',5'-dinucleoside triphosphate catabolism by APH1, a Saccharomyces cerevisiae analog of human FHIT. J Bacteriol (1998) 0.86
Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol (2002) 0.85
Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis (2012) 0.83
Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues. Mol Cancer (2007) 0.83
Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J Gastroenterol (2005) 0.81
Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers. Br J Cancer (2004) 0.81
Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions. Br J Cancer (2002) 0.81
Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer (2000) 0.80
Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers. Br J Cancer (2003) 0.79
WWOX, large common fragile site genes, and cancer. Exp Biol Med (Maywood) (2015) 0.78
HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer. Br J Cancer (1999) 0.76
FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol (2009) 0.76
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
The Indirect Efficacy Comparison of DNA Methylation in Sputum for Early Screening and Auxiliary Detection of Lung Cancer: A Meta-Analysis. Int J Environ Res Public Health (2017) 0.75
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene (1998) 4.88
Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 4.84
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A (1980) 3.39
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
NCI series of cell lines: an historical perspective. J Cell Biochem Suppl (1996) 2.75
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP(Sc) in the same brain. Neurology (1999) 2.33
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett (1988) 2.26
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol (1998) 2.15
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest (1993) 2.06
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Primary lung cancer: characterization and survival of 1024 patients treated in a single institution. Med J Aust (1990) 2.04
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Purification and characterization of a maturation-activated myelin basic protein kinase from sea star oocytes. J Biol Chem (1990) 2.03
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Gene mapping in Mus musculus by interspecific cell hybridization: assignment of the genes for tripeptidase-1 to chromosome 10, dipeptidase-2 to chromosome 18, acid phosphatase-1 to chromosome 12, and adenylate kinase-1 to chromosome 2. Cytogenet Cell Genet (1977) 1.98